Gold prices steady ahead of Fed decision; weekly weakness noted
Tommy G. Thompson, a director at TherapeuticsMD, Inc. (NASDAQ:TXMD), recently made a notable transaction involving the company’s common stock. The micro-cap company, currently valued at approximately $12 million, has shown strong momentum with a 17% gain over the past week. According to InvestingPro analysis, the company maintains a "GOOD" overall financial health score. On April 14, 2025, Thompson purchased 325 shares, valued at approximately $325. The shares were acquired at a weighted average price of $1.0018 each, with individual transaction prices ranging from $0.99 to $1.05. Following this purchase, Thompson holds a total of 14,779 shares directly. Additionally, Thompson maintains indirect ownership through Thompson Family Holdings, LLC, and Thompson Family Investments, LLC, which collectively hold 14,333 shares. With the company’s next earnings report scheduled for May 8, 2025, InvestingPro subscribers can access 8 additional key insights about TXMD’s financial outlook and valuation metrics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.